| Nov 13 |
BioAge Labs Reports Strong Q3 2024 Achievements
|
| Nov 8 |
BioAge Labs, Inc. GAAP EPS of -$6.70
|
| Nov 7 |
BioAge Labs Reports Third Quarter 2024 Financial Results and Provides Business Updates
|
| Nov 4 |
BioAge Labs to Present Preclinical Data for APJ Agonist Azelaprag at ObesityWeek 2024
|
| Oct 24 |
BioAge Labs to Present at Jefferies London Healthcare Conference
|
| Oct 21 |
Goldman Sachs, Morgan Stanley bullish on BioAge, cite Lilly relationship
|
| Oct 21 |
Wall Street analysts initiate coverage of BioAge Labs
|
| Oct 17 |
Prediction: These 2 Stocks Could Soar in 2025
|
| Oct 12 |
Interested in Weight Loss Stocks Besides Novo Nordisk and Eli Lilly? You Might Want To Check Out This New IPO Stock
|
| Oct 8 |
RA Capital Management, L.P. Acquires New Stake in Bioage Labs Inc
|
